10x Science raises $4.8M seed round for drug molecule analysis

In short: 10x Science raised $4.8 million in seed funding to help drug researchers figure out which lab-made drug candidates are worth moving forward.

What happened

10x Science is a startup founded in December 2025. It announced a $4.8 million seed round led by Initialized Capital, with backing from Y Combinator, Civilization Ventures, and Founder Factor.

The company is focused on a growing problem in drug research. AI tools can suggest huge numbers of possible new medicines, but scientists still have to check what those molecules really are before they can test them and later manufacture them.

10x Science aims to speed up that checking step using mass spectrometry, a lab method that helps identify what a molecule is by measuring it in an electric field (like weighing and sorting tiny pieces based on how they move). Mass spectrometry can be accurate, but the results can be hard to read and time-consuming to analyze.

According to TechCrunch, 10x Science combines traditional rules-based software with AI systems that help interpret the mass spectrometry data. A scientist at Rilas Technologies told TechCrunch he has been using the platform for weeks and that it has sped up his work, including automatically pulling helpful information from file names and online databases.

10x Science said it plans to use the funding to hire more engineers, improve the product, and expand to more customers, including large pharmaceutical companies and academic labs.

Why it matters

Even if AI can suggest many possible drugs, progress still slows down if labs cannot quickly confirm what those candidates are. Tools that make this step faster could help researchers spend more time testing the most promising ideas, and less time untangling confusing lab data.

Source: TechCrunch AI